The oral anticoagulant Xarelto ( Rivaroxaban ) has been approved by the European Commission for the prevention of atherothrombotic events ( cardiovascular death, myocardial infarction or stroke ) after an acute coronary syndrome ( ACS ) in adult patients with elevated cardiac biomarkers at a dose of 2.5 mg twice-daily ( BID ) in combination with standard antiplatelet therapy.
This approval makes Rivaroxaban the only novel oral anticoagulant approved to protect patients with elevated cardiac biomarkers following an acute coronary syndrome.
Arterial blood clots, which may lead to a recurrence after an acute coronary syndrome, are formed through the dual pathways of platelet activation and thrombin generation. Standard antiplatelet therapy only targets the platelet activation pathway of clot formation. Rivaroxaban targets factor Xa, a key trigger of thrombin generation.
The thrombin levels remain elevated long after an ACS event, leaving patients at risk. In the ATLAS ACS 2-TIMI 51 study, researchers have shown that treating these patients with a low dose of Rivaroxaban in combination with standard antiplatelet therapy targets both pathways of clot formation providing more complete long-term protection, including significant reduction in mortality risk.
The approval of Rivaroxaban in this indication is based on important clinical findings of the pivotal Phase III ATLAS ACS 2-TIMI 51 study of more than 15,500 patients. The study demonstrated that the addition of Rivaroxaban 2.5 mg BID to standard antiplatelet therapy ( low-dose Acetylsalicylic Acid [ Aspirin ] with or without a thienopyridine ( Clopidogrel [ Plavix ] or Ticlopidine [ Tiklid ] ), significantly reduced the composite primary efficacy endpoint of cardiovascular death, myocardial infarction or stroke in patients after a recent acute coronary syndrome compared to those who received standard antiplatelet therapy alone.
Rates of TIMI ( Thrombolysis In Myocardial Infarction ) major bleeding events not associated with coronary artery bypass graft ( CABG ) surgery and of intracranial haemorrhage ( ICH ) were low overall, yet increased with the addition of Rivaroxaban. But importantly, there was no increase observed with Rivaroxaban in the risk of fatal intracranial haemorrhage or fatal bleeding.
Based on the ATLAS ACS 2-TIMI 51 study findings, the 2012 European Society of Cardiology ( ESC ) Guidelines recommend that treatment with Rivaroxaban 2.5 mg BID be considered for patients with ST-segment elevation myocardial infarction ( STEMI ) who are at low bleeding risk and are on antiplatelet therapy with Acetylsalicylic Acid and Clopidogrel.
Source: Bayer HealthCare, 2013